Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany.
J Am Chem Soc. 2009 Dec 30;131(51):18478-88. doi: 10.1021/ja907795q.
Small molecule kinase inhibitors are an attractive means to modulate kinase activities in medicinal chemistry and chemical biology research. In the physiological setting of a cell, kinase function is orchestrated by a plethora of regulatory processes involving the structural transition of kinases between inactive and enzymatically competent conformations and vice versa. The development of novel kinase inhibitors is mainly fostered by high-throughput screening initiatives where the small molecule perturbation of the phosphorylation reaction is measured to identify inhibitors. Such setups require enzymatically active kinase preparations and present a risk of solely identifying classical ATP-competitive Type I inhibitors. Here we report the high-throughput screening of a library of approximately 35000 small organic molecules with an assay system that utilizes enzymatically inactive human p38alpha MAP kinase to detect stabilizers of the pharmacologically more desirable DFG-out conformation. We used protein X-ray crystallography to characterize the binding mode of hit compounds and reveal structural features which explain how these ligands stabilize and/or induce the DFG-out conformation. Lastly, we show that although some of the hit compounds were confirmed by protein X-ray crystallography, they were not detected in classic phosphorylation assays, thus validating the unique sensitivity of the assay system used in this study and highlighting the potential of screening with inactive kinase preparations.
小分子激酶抑制剂是调节医学化学和化学生物学研究中激酶活性的一种有吸引力的手段。在细胞的生理环境中,激酶的功能是由大量的调节过程来协调的,这些过程涉及到激酶在非活性和酶活性构象之间的结构转变,反之亦然。新型激酶抑制剂的开发主要得益于高通量筛选计划,在这些计划中,通过测量磷酸化反应中小分子的扰动来识别抑制剂。这种设置需要具有酶活性的激酶制剂,并且存在仅识别经典 ATP 竞争性 I 型抑制剂的风险。在这里,我们报告了利用一种酶非活性的人 p38alpha MAP 激酶检测更理想的 DFG-out 构象稳定剂的测定系统,对大约 35000 种小分子有机化合物文库进行高通量筛选。我们使用蛋白质 X 射线晶体学来描述命中化合物的结合模式,并揭示解释这些配体如何稳定和/或诱导 DFG-out 构象的结构特征。最后,我们表明,尽管一些命中化合物通过蛋白质 X 射线晶体学得到了证实,但它们在经典磷酸化测定中没有被检测到,从而验证了本研究中使用的测定系统的独特敏感性,并强调了用非活性激酶制剂筛选的潜力。